Edition:
United Kingdom

La Jolla Pharmaceutical Co (LJPC.OQ)

LJPC.OQ on NASDAQ Stock Exchange Capital Market

22.74USD
14 Aug 2018
Change (% chg)

$0.17 (+0.75%)
Prev Close
$22.57
Open
$22.75
Day's High
$22.85
Day's Low
$22.38
Volume
35,599
Avg. Vol
133,923
52-wk High
$41.24
52-wk Low
$21.49

Chart for

About

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant... (more)

Overall

Beta: 1.70
Market Cap(Mil.): $794.45
Shares Outstanding(Mil.): 22.12
Dividend: --
Yield (%): --

Financials

  LJPC.OQ Industry Sector
P/E (TTM): -- 85.68 32.76
EPS (TTM): -5.15 -- --
ROI: -80.11 1.78 14.61
ROE: -84.81 3.28 16.33

BRIEF-La Jolla PharmaAnnounces Launch Of Giapreza In United States

* LA JOLLA PHARMACEUTICAL COMPANY ANNOUNCES LAUNCH OF GIAPREZA™ (ANGIOTENSIN II) IN THE UNITED STATES

22 Mar 2018

BRIEF-La Jolla Pharmaceutical Announces Pricing Of Public Offering Of Common Stock

* SAYS PUBLIC OFFERING OF 3.40 MILLION COMMON SHARES PRICED AT $29.50PER SHARE

15 Mar 2018

BRIEF-La Jolla Pharmaceutical Company Announces $100 Million Public Offering Of Common Stock

* LA JOLLA PHARMACEUTICAL COMPANY ANNOUNCES $100 MILLION PUBLIC OFFERING OF COMMON STOCK Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

14 Mar 2018

BRIEF-La Jolla Pharmaceutical Q4 Loss Per Share $1.74

* MPANY ANNOUNCES FINANCIAL RESULTS FOR THE THREE AND TWELVE MONTHS ENDED DECEMBER 31, 2017 AND RECENT CORPORATE PROGRESS

22 Feb 2018

BRIEF-La Jolla Pharmaceutical Announces Treatment Of First Patient In Giapreza Pediatric Study

* LA JOLLA PHARMACEUTICAL COMPANY ANNOUNCES THE TREATMENT OF FIRST PATIENT IN GIAPREZA (ANGIOTENSIN II) PEDIATRIC STUDY Source text for Eikon: Further company coverage:

21 Feb 2018

Competitors

Earnings vs. Estimates